ZLAB Company Profile and Key Details

ZLAB has shown mixed momentum, gaining 2.83% over the past week and -33.16% over the past quarter, though year-to-date performance is up 7.2%. Short-term trend indicators are mixed aligned (SMA20 5.61%, SMA50 7.59%, SMA200 -29.4%). The stock’s 14-day RSI is 58.12 (neutral), while the ATR of 0.82 points to higher daily volatility. The stock remains sitting in the mid-range of its 52-week band, trading -55.59% below its high and over 23.37% above its low. Average 10-day trading volume of 946.96 thousand shares is in line with the 3-month average of 985.56 thousand, indicating normal recent market interest.

Zai Lab Limited generated EPS of -$1.95 over the past year. Five-year average earnings growth is -3.16%. Wall Street analysts project EPS growth of 38.86% annually over the next five years. Analyst sentiment is bullish. Analyst rating data shows there are 3 Strong Buy ratings, 2 Buy ratings, 0 Hold ratings, 0 Sell rating and 0 Strong Sell ratings. Price targets range from $55.00 to $32.00. The high target offers 114.01% upside. The low target suggests 24.51% downside. The mean target is $41.00. This offers 59.53% upside. Zai Lab Limited earnings surprise history is a mixed track record. The quarter that ended August 06, 2026, missed forecasts by -32.29%. The prior quarter beat by -12.57%. Over the last six quarters, Apple has recorded several small beats. These include -10.0% in May 08, 2025.

Zai Lab Limited (NASDAQ:ZLAB) closed at $25.70 USD, losing -$0.11 (-0.43%) from the previous close of $25.81. The stock is currently mid-range between its 52-week high and low $15.96 and $34.72. With a market capitalization of about $2.90 billion, Zai Lab Limited is classified as a mid-cap and shows market-like volatility (beta ~0.83). Key stats such as the average daily volume over the past year has been around 987.52 thousand shares, in line with its 52-week average. Headquartered in Shanghai, SH, Zai Lab Limited operates in the Healthcare sector and the Biotechnology industry. Led by CEO Ying Du, the company employs approximately 1,784 people and listed since September 20, 2017. Operating primarily in Mainland China and Hong Kong, Zai Lab Limited is a biopharmaceutical company focused on the discovery, development, and commercialization of innovative medical treatments.

Zai Lab Limited has 112.27 million shares outstanding. The public float is 96.83 million shares, elevated short interest at 5.94% of float. This equals 6.53 million shares. The short ratio is 9.02 days. Institutional investors hold 42.68% of the float. Insiders own 2.15%. Du Ying holds 1.20 million shares, Smiley Joshua L has 117.60 thousand shares and GAYNOR RICHARD has 80.74 thousand shares. Over the past six months, insider transactions show net selling. They sold 199.34 thousand shares across 20 transactions.

Zai Lab Limited last paid a dividend of 0 per share, Dividend and splits history remains an important factor for investors monitoring long-term returns. A discounted cash flow model estimates fair value at around -$37.97. This means the shares are trading below this model’s fair value.

Zai Lab Limited trades at a P/E ratio of -14.33, slightly below the S&P 500 average, with a price-to-sales ratio of 6.44 and a price-to-book ratio of 4.72 trading at moderately above to book value. The P/FCF stands at -17.82, also below market averages.

Zai Lab Limited (NASDAQ:ZLAB) shares are flat 7.2% year-to-date currently trading near 52-week highs band. Short-term momentum has been negative over the last quarter, despite recent volatility. Valuation shows Zai Lab Limited trading at a premium to the broader market with a P/E of -14.33. Analyst sentiment is bullish, with the majority of ratings in Buy territory and a mean price target of $62.32, suggesting 142.49% upside. Our AI forecast model points to short-term weakness (-2.65% over two weeks), a medium-term fall (-65.68% over three months), and a longer-term gain (4.9% over one year), with expected trading ranges indicating moderate volatility.

Our AI price prediction model suggests that Zai Lab Limited stock has strong potential for upside but may face short-term weakness followed by gains in the medium and long term. 2-Week Outlook: Projected decline of -2.65%, with price expected at $25.02 by October 02, 2026, within a range of $23.77 to $26.29 3-Month Outlook: Projected fall of -65.68%, reaching $8.82 by December 16, 2026, with a range of $7.23 to $9.74. 1-Year Outlook: Projected gain of 4.9%, with price at $26.96 by September 17, 2027, within a range of $24.64 to $29.29.